Scandinavian Journal of Immunology最新文献

筛选
英文 中文
Hemophagocytic Lymphohistiocytosis: Proposal for a New Terminology. 噬血细胞性淋巴组织细胞病:一个新术语的建议。
IF 1.6 4区 医学
Scandinavian Journal of Immunology Pub Date : 2026-03-01 DOI: 10.1111/sji.70104
Büşra Koçali, Deniz Çağdaş
{"title":"Hemophagocytic Lymphohistiocytosis: Proposal for a New Terminology.","authors":"Büşra Koçali, Deniz Çağdaş","doi":"10.1111/sji.70104","DOIUrl":"https://doi.org/10.1111/sji.70104","url":null,"abstract":"","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"103 3","pages":"e70104"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147481723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond the Scar: What Can a Persistent BCG Vaccine Reaction in Infants Tell Us in an Immunological Point of View? 超越疤痕:婴儿持续卡介苗反应从免疫学角度告诉我们什么?
IF 2.4 4区 医学
Scandinavian Journal of Immunology Pub Date : 2026-03-01 DOI: 10.1111/sji.70099
Gonca Keskindemirci, Ece Aslan, Esra Yücel, Selda Hançerli Törün, Şimal Cetişli, Öykü Özbörü Aşkan, Alev Bakır Kayı, Gülbin Gökçay
{"title":"Beyond the Scar: What Can a Persistent BCG Vaccine Reaction in Infants Tell Us in an Immunological Point of View?","authors":"Gonca Keskindemirci, Ece Aslan, Esra Yücel, Selda Hançerli Törün, Şimal Cetişli, Öykü Özbörü Aşkan, Alev Bakır Kayı, Gülbin Gökçay","doi":"10.1111/sji.70099","DOIUrl":"10.1111/sji.70099","url":null,"abstract":"<p><p>The aim of this study was to evaluate children who still have not yet developed scar at the BCG vaccination site 16 weeks after vaccine administration without any local and systemic adverse reactions. The files of all children who were born between 01 Jan 2018 and 31 Dec 2023 were evaluated. BCG vaccine reaction status at the 6th month (completion with formation of scar or persistent reaction or abortive reaction), if any, further investigations performed in children with persistent BCG vaccine reaction without local or systemic adverse reactions; immunoglobulin (Ig) G, IgM, IgA, complete blood count, lymphocyte subgroup examination results, follow-up results and reaction completion time, and diagnoses were recorded. In our retrospective cohort study, the files of 962 children were evaluated. Of the 962 children, 22 of them had persistent BCG vaccine reaction at 6th months of age. Four of 22 children had low levels of IgG, IgM and IgA; 4 had low levels of both IgA and IgG; 3 had low levels of only IgG. There was no statistical significance in terms of blood count, birth weight, gender, BCG vaccine administration time, exclusively breastfeeding duration between children with persistent BCG reaction with low Ig levels and normal Ig levels. BCG reaction completion mean day was 268 (±33.3). Nine of 22 were diagnosed with transient hypogammaglobulinemia of infant (THI). Our study shows that THI may be considered in persistent BCG reactions without local or systemic adverse reactions. Further studies are needed for evaluating persistent BCG reactions.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"103 3","pages":"e70099"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147271831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Organoids in Personalised Oncology: Advances and Clinical Translation Toward Precision Cancer Therapy. 个体化肿瘤中的类器官:向精确癌症治疗的进展和临床转化。
IF 2.4 4区 医学
Scandinavian Journal of Immunology Pub Date : 2026-03-01 DOI: 10.1111/sji.70107
Shurong Hai, Xishun Zhou, Junbo Li, Xi Zeng, Qi Yu
{"title":"Organoids in Personalised Oncology: Advances and Clinical Translation Toward Precision Cancer Therapy.","authors":"Shurong Hai, Xishun Zhou, Junbo Li, Xi Zeng, Qi Yu","doi":"10.1111/sji.70107","DOIUrl":"10.1111/sji.70107","url":null,"abstract":"<p><p>Cancer remains one of the most pressing global health challenges due to its high incidence and mortality. Intratumoral and intertumoral heterogeneity pose significant challenges to effective treatment, driving metastasis, recurrence, therapeutic resistance and ultimately treatment failure. The development of precision medicine urgently requires in vitro models that can faithfully capture patient-specific tumour complexity to guide individualised therapies. Recent advances in stem cell-based three-dimensional culture technologies have facilitated the establishment of organoid systems that closely replicate the architecture, molecular features, genomic alterations and microenvironment of primary tumours. Compared with conventional cell lines, organoids exhibit superior fidelity, making them a transformative platform for cancer modelling. They hold considerable promise for high-throughput drug screening, therapeutic response prediction, biomarker discovery and the design of personalised treatment strategies. Despite these advances, clinical translation is still hindered by challenges, such as the lack of standardisation, prolonged culture periods, high costs and regulatory and ethical constraints. This review summarises recent progress in tumour organoid research, with particular emphasis on their ability to replicate the genetic and biological features of parental tumours. We highlight their translational applications in immunotherapy, drug sensitivity prediction and individualised treatment, while also proposing strategies to address current limitations aiming to accelerate the integration of organoid technologies into precision oncology.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"103 3","pages":"e70107"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147475114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunogenicity, Safety and Immune Persistence of Sabin Strain Inactivated Poliovirus Vaccine: A Phase III Clinical Trial. Sabin株脊髓灰质炎病毒灭活疫苗的免疫原性、安全性和免疫持久性:一项III期临床试验
IF 2.4 4区 医学
Scandinavian Journal of Immunology Pub Date : 2026-03-01 DOI: 10.1111/sji.70097
Teng Huang, Cong Wu, Zhifang Ying, Zhongyang Zhang, Qingliang Li, Weiwei Lu, Gang Yu, Pengliang Hao, Shiyi Liu, Huijie Guo, Junhui Tao, Yujuan Yang, Chencai Tao, Wei Chen, Jiayou Zhang, Xiuling Li
{"title":"Immunogenicity, Safety and Immune Persistence of Sabin Strain Inactivated Poliovirus Vaccine: A Phase III Clinical Trial.","authors":"Teng Huang, Cong Wu, Zhifang Ying, Zhongyang Zhang, Qingliang Li, Weiwei Lu, Gang Yu, Pengliang Hao, Shiyi Liu, Huijie Guo, Junhui Tao, Yujuan Yang, Chencai Tao, Wei Chen, Jiayou Zhang, Xiuling Li","doi":"10.1111/sji.70097","DOIUrl":"10.1111/sji.70097","url":null,"abstract":"<p><p>The phased transition from oral poliovirus vaccine (OPV) to full-course immunisation with inactivated poliovirus vaccine (IPV) is a critical strategy for the global eradication of poliomyelitis. A randomised, double-blind, multi-centre, active-controlled clinical trial was conducted among healthy infants in China to evaluate the immunogenicity and safety of the Sabin strain IPV (sIPV). A total of 1260 healthy 2-month-old infants who had not previously received poliovirus vaccination were randomly assigned to receive three doses of either the investigational vaccine (sIPV) or the control vaccine (wIPV) according to a 0-, 28- and 56-day schedule, followed by a booster dose at 18 months of age. Per-protocol analysis (sIPV: n = 563; wIPV: n = 561) showed postprimary seroconversion rates for sIPV versus wIPV were: Type 1 (97.69% vs. 94.65%), Type 2 (98.22% vs. 87.70%) and Type 3 (99.82% vs. 98.57%). sIPV met noninferiority criteria (margin: -5%) for all serotypes, with one-sided 97.5% CI lower limits exceeding this margin. Postbooster geometric mean titre (GMT) for sIPV were 7297.40 (Type 1), 8490.51 (Type 2) and 7158.27 (Type 3), indicating robust immune memory. Safety profiles were similar overall, though sIPV had higher incidences of fever and hypersensitivity reactions. Serious adverse event rates were comparable (sIPV: 2.86% vs. wIPV: 2.70%). The study confirms sIPV's immunogenicity is noninferior to wIPV, with a potent booster response and acceptable safety. The trial was registered with chinadrugtrials.org.cn (CTR20170648).</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"103 3","pages":"e70097"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146228391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking Immune Checkpoint Inhibition in Cancer. 癌症免疫检查点抑制的再思考
IF 2.4 4区 医学
Scandinavian Journal of Immunology Pub Date : 2026-03-01 DOI: 10.1111/sji.70106
Tibor Bakacs, Colin C Anderson
{"title":"Rethinking Immune Checkpoint Inhibition in Cancer.","authors":"Tibor Bakacs, Colin C Anderson","doi":"10.1111/sji.70106","DOIUrl":"10.1111/sji.70106","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have reshaped cancer treatment, offering durable remissions for a minority of patients. Yet their success has come with a difficult trade-off: a large proportion of patients develop immune-related adverse events (irAEs), sometimes severe, and often without gaining clinical benefit. These reactions signal a disruption of peripheral tolerance that is not easily explained by traditional models in which negative selection of autoreactive T cells maintains self-restraint. Under ICI therapy, patients' own T cells can behave in ways that resemble the alloreactive responses seen in chronic graft-versus-host disease (cGVHD), producing a pattern of tissue injury that mirrors this well-studied transplant complication. This parallel offers a fresh way to think about why irAEs occur and how they might be prevented. Despite arising from fundamentally different immunologic triggers, comparative transcriptomic analyses reveal that cGVHD and irAEs induced by ICIs converge on a common molecular ecosystem dominated by interferon-conditioned tissue states. Early clinical experience with ultra-low-dose ICI regimens supports this idea, showing that meaningful antitumor activity can be preserved while dramatically reducing toxicity. We suggest that viewing ICI-induced autoimmunity through a cGVHD-like lens may help guide safer dosing strategies and broaden access to immunotherapy worldwide.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"103 3","pages":"e70106"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147435226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Thymic Hypoplasia to Immune Reconstitution: An Immunological Review of DiGeorge Syndrome. 从胸腺发育不全到免疫重建:迪乔治综合征免疫学综述。
IF 2.4 4区 医学
Scandinavian Journal of Immunology Pub Date : 2026-03-01 DOI: 10.1111/sji.70103
Alejandro Tarango-García, Hanadys Ale, Hannia Michelle Prieto-Nevárez, Saul O Lugo Reyes
{"title":"From Thymic Hypoplasia to Immune Reconstitution: An Immunological Review of DiGeorge Syndrome.","authors":"Alejandro Tarango-García, Hanadys Ale, Hannia Michelle Prieto-Nevárez, Saul O Lugo Reyes","doi":"10.1111/sji.70103","DOIUrl":"10.1111/sji.70103","url":null,"abstract":"<p><p>DiGeorge syndrome (DGS), also known as 22q11.2 deletion syndrome, is the most prevalent chromosomal microdeletion syndrome. It presents with a heterogeneous phenotype and diverse clinical manifestations, which may include, but are not limited to, cardiovascular, endocrine, neurodevelopmental and immune function abnormalities. The immune defects seen in individuals with DGS arise from impairment in thymus development, resulting in immune dysregulation. This thymic dysfunction impairs T-cell development and maturation, leading to a spectrum of T-cell lymphopenia, a restricted T-cell receptor repertoire and defects relating to regulatory T cells. Consequently, patients exhibit increased susceptibility to recurrent infections, particularly of the respiratory tract and a higher prevalence of autoimmune conditions and atopic diseases. The present literature review synthesises current knowledge on the immunopathogenic mechanisms, clinical manifestations and treatment approaches for the immune dysregulation in DGS.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"103 3","pages":"e70103"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147277096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Enigma of CD1d-iNKT Axis in Leishmaniases: Current Insights Into Immune Regulation. 利什曼病cd1 - inkt轴之谜:当前免疫调节的见解。
IF 2.4 4区 医学
Scandinavian Journal of Immunology Pub Date : 2026-03-01 DOI: 10.1111/sji.70102
Syamdas Bandyopadhyay, Surya Prakash Pandey
{"title":"The Enigma of CD1d-iNKT Axis in Leishmaniases: Current Insights Into Immune Regulation.","authors":"Syamdas Bandyopadhyay, Surya Prakash Pandey","doi":"10.1111/sji.70102","DOIUrl":"10.1111/sji.70102","url":null,"abstract":"<p><p>Leishmaniases caused by Leishmania parasites may be fatal if proper treatment is lacking. These protozoan parasites employ several strategies to control the host immune system. Among these, manipulation of the antigen presentation pathway is crucial for survival in the host. In addition to protein antigens produced by Leishmania sp. parasite-derived lipid or glycolipid antigens are known which are potentially important at the interface of host-parasite interactions. CD1d is a cell surface-expressed receptor that presents both endogenous and exogenous lipids and glycolipids to the TCR of invariant NKT cells. The CD1d-iNKT axis is important during the initial stages of infection by several species of Leishmania, although it may not be required for resolution of the infection at a later stage in mice. Owing to the limited number of published reports, heterogeneity in response is evident in both mice and human. Organ-specific, host species-specific and parasite species-specific responses make the concept even more complex. In this review, we comprehensively summarise the role of the CD1d-iNKT axis in the regulation of Leishmania infection. A deeper understanding of the mechanistic role of the CD1d-iNKT axis during Leishmania infection in human may provide a foundation for the rational design of targeted immunotherapeutic interventions in the future.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"103 3","pages":"e70102"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147284962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Augmenting the Jeffrey Modell Criteria for Optimising Screening for Inborn Errors of Immunity. 增强Jeffery模型标准以优化先天性免疫缺陷筛查。
IF 2.4 4区 医学
Scandinavian Journal of Immunology Pub Date : 2026-02-01 DOI: 10.1111/sji.70092
Reetika Malik Yadav, Lavina Temkar, Umair Ahmed Bargir, Maya Gupta, Aparna Dalvi, Shweta Shinde, Manisha Madkaikar
{"title":"Augmenting the Jeffrey Modell Criteria for Optimising Screening for Inborn Errors of Immunity.","authors":"Reetika Malik Yadav, Lavina Temkar, Umair Ahmed Bargir, Maya Gupta, Aparna Dalvi, Shweta Shinde, Manisha Madkaikar","doi":"10.1111/sji.70092","DOIUrl":"10.1111/sji.70092","url":null,"abstract":"<p><p>Jeffrey Modell warning signs have been used to guide screening for inborn errors of immunity (IEIs) for over three decades now, but may lack sensitivity for noninfectious presentations. Our study explored JMF signs along with additional signs and some laboratory parameters and assessed their effectiveness for guiding molecular screening for IEIs. We retrospectively analysed 100 patients suspected of IEI referred to ICMR-National Institute of Immunohaematology from immunology clinics who underwent whole-exome sequencing (WES), with pathogenic (n = 50) and no variants (n = 50). We evaluated clinical presentations other than JMF-autoimmunity, autoinflammation, vaccine complications, fever with bi-cytopenia, consanguinity and laboratory parameters-absolute lymphocyte count, low naïve T cell (%) and hypogammaglobulinaemia at initial presentation. Thirty-two models with different combinations of additional signs along with JMF score were evaluated based on the AIC score to determine the best model. The model was validated on WES results of 219 patients. The JMF scores of the pathogenic/likely pathogenic group (3.54 ± 1.92) were significantly higher than those of the no variants group (1.34 ± 1.28) (p < 0.05). The best model, inclusive of consanguinity, presence of autoimmunity, vaccine complications, hypogammaglobulinaemia and low naïve T cell (%) with JMF, had a sensitivity and specificity of 82% and 67%, respectively, compared to sensitivity and specificity of 84% and 61% for JMF alone. Our study shows that the presence of any two among parental consanguinity, presence of autoimmunity, vaccine complications and low naïve T cell (%) improves the specificity of JMF criteria in guiding molecular screening for IEIs.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"103 2","pages":"e70092"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD71+ Red Blood Cells Mediate Increased Erythrophagocytosis and Reduce Monocyte Number in a Monocyte Suspension Assay. CD71+红细胞介导单核细胞悬浮试验中红细胞吞噬增加和单核细胞数量减少。
IF 2.4 4区 医学
Scandinavian Journal of Immunology Pub Date : 2026-02-01 DOI: 10.1111/sji.70087
Wenhui Li, Jason P Acker
{"title":"CD71<sup>+</sup> Red Blood Cells Mediate Increased Erythrophagocytosis and Reduce Monocyte Number in a Monocyte Suspension Assay.","authors":"Wenhui Li, Jason P Acker","doi":"10.1111/sji.70087","DOIUrl":"10.1111/sji.70087","url":null,"abstract":"<p><p>Adverse reactions from donor-recipient sex-mismatched transfusions have been reported in the field of transfusion medicine. Immature CD71<sup>+</sup> red blood cells (CD71<sup>+</sup> RBCs) may influence these reactions through an immunomodulatory mechanism potentially linked to enriched intracellular reactive oxygen species (ROS). This study was conducted to investigate the effect of CD71<sup>+</sup> RBCs on erythrophagocytosis, a common in vitro test for hemolysis risk in incompatible blood transfusions. Enriched CD71<sup>+</sup> RBCs and CD71<sup>-</sup> RBCs were exposed to allogenic peripheral blood mononuclear cells (PBMCs). CD71<sup>+</sup> RBCs were also incubated with anti-D sensitised CD71<sup>-</sup> RBCs and PBMCs, in varying ratios, to assess any dose-dependent behaviour. An ROS scavenger, apocynin, was applied to understand how CD71<sup>+</sup> RBCs impact erythrophagocytosis. The phagocytosis index (RBC PI or CD71<sup>+</sup> RBC PI) was measured using image flow cytometry. Supernatant haemoglobin was examined spectrophotometrically. The enriched CD71<sup>+</sup> RBC group showed a significantly higher RBC PI and a reduction in the monocyte number compared to the CD71<sup>-</sup> RBC group. Compared to the non-treated group, the reduction of monocyte number and the increase of the phagocytosis index of CD71<sup>+</sup> RBCs was partially reversed in the apocynin-treated group. There were positive correlations between the dose of CD71<sup>+</sup> RBC and CD71<sup>+</sup> RBC PI and supernatant haemoglobin. Donated CD71<sup>+</sup> RBCs enhance in vitro erythrophagocytosis of CD71<sup>+</sup> RBCs in a dose-dependent manner and reduce monocyte number. This work contributes to our understanding of immature CD71<sup>+</sup> RBCs' role in post-transfusion immunobiology.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"103 2","pages":"e70087"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remarkable Rituximab Response in a Chronic Granulomatous Disease Patient on the Verge of a Lung Transplant. 一名即将进行肺移植的慢性肉芽肿病患者的显著利妥昔单抗反应
IF 1.6 4区 医学
Scandinavian Journal of Immunology Pub Date : 2026-02-01 DOI: 10.1111/sji.70096
Zehra Genc Ozbay, Deniz Ilgun Gurel, Ozge Ozturk Aktas, Deniz Cagdas
{"title":"Remarkable Rituximab Response in a Chronic Granulomatous Disease Patient on the Verge of a Lung Transplant.","authors":"Zehra Genc Ozbay, Deniz Ilgun Gurel, Ozge Ozturk Aktas, Deniz Cagdas","doi":"10.1111/sji.70096","DOIUrl":"10.1111/sji.70096","url":null,"abstract":"","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"103 2","pages":"e70096"},"PeriodicalIF":1.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书